Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, announced a $28 million investment from its parent company, HLB Innovation. The investment comes ahead of a significant clinical milestone: the first-ever presentation of KIR-CAR clinical data, which will be featured in the Late-Breaking Clinical Trials plenary session at the American Association for Cancer Research Annual Meeting 2026 in San Diego, CA, on April 20, 2026.